Trial · NCT03508687
Outcomes19
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 19 of 19
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Change in Fasting Serum Triglyceride (at 12 Weeks) | Baseline to week 12 | percent change | MEAN | |
| SECONDARY | Change in Fasting Serum Triglycerides (Through 24 Weeks) | Baseline, week 6 and week 12, week 24 | mg/dL | MEAN | |
| SECONDARY | Percent Change in Fasting Serum Triglycerides (Through 24 Weeks) | Baseline, week 6 and week 12, week 24 | percent change | MEAN | |
| SECONDARY | Change in Liver Fat Content as Measured by Magnetic Resonance Imaging - Protein Density Fat Fraction (MRI-PDFF) | Baseline, week 12, week 24 | % PDFF | MEAN | |
| SECONDARY | Percent Change in Liver Fat Content as Measured by Magnetic Resonance Imaging - Protein Density Fat Fraction (MRI-PDFF) | Baseline, week 12, week 24 | percent change in liver fat | MEAN | |
| SECONDARY | Change in Liver Fibrosis | Baseline, Week 12, and Week 24 | Percentage of change in Preliminary Hepatic Fat-Fraction (PDFF) | kPA | MEAN |
| SECONDARY | Percent Change in Liver Fibrosis | Baseline, Week 12, and Week 24 | percent change in fibrosis | MEAN | |
| SECONDARY | Change in NAS (Non-alcoholic Steatohepatitis) | Baseline to week 24 | Liver biopsy was performed in two participants at baseline (1 subject in group-1 and another subject in group-2).~Paired liver biopsy was only available for the subject in group-1. | scores on a scale (NAFLD activity score) | MEAN |
| SECONDARY | Percent Change in NAS (Non-alcoholic Steatohepatitis) | Baseline to week 24 | percent change | MEAN | |
| SECONDARY | Change in Cholesterol | Baseline, week 6 and week 12, week 24 | mg/dL | MEAN | |
| SECONDARY | Percent Change in Cholesterol | Baseline, week 6 and week 12, week 24 | percent change | MEAN | |
| SECONDARY | Change in Apolipoprotein | Baseline, week 6 and week 12, week 24 | mg/dL | MEAN | |
| SECONDARY | Percent Change in Apolipoprotein | Baseline, week 6 and week 12, week 24 | % Change in participants in group A and group B | percent change | MEAN |
| SECONDARY | Change in High-Sensitivity C-Reactive Protein (hsCRP) | Baseline, week 12, week 24 | mg/dL | MEAN | |
| SECONDARY | Percent Change in High-Sensitivity C-Reactive Protein (hsCRP) | Baseline, week 12, week 24 | percent change | MEAN | |
| SECONDARY | Change in Alanine Aminotransferase (ALT) | Baseline, week 12, week 24 | IU/L | MEAN | |
| SECONDARY | Percent Change in Alanine Aminotransferase (ALT) | Baseline, week 12, week 24 | percent change | MEAN | |
| SECONDARY | Change in Aspartate Aminotransferase (AST) | Baseline, week 12, week 24 | IU/L | MEAN | |
| SECONDARY | Percent Change in Aspartate Aminotransferase (AST) | Baseline, week 12, week 24 | percent change | MEAN |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03508687/outcomes